Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus low dose (greater than or… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Feasibility and engagement: lost to · patients with acute psychiatric disorders
Day hospital showed no clear difference in feasibility and engagement: lost to compared with inpatient (moderate certainty).
1 finding from 1 review
Extent of hospital care: 1. duration of index admission · patients with acute psychiatric disorders
1 finding from 1 review
Unemployed (at end of study) · patients with acute psychiatric disorders
Day hospital may leads to lower unemployed (at end of study) compared with inpatient (low certainty).
1 finding from 1 review
Quality of Life Manchester Short Assessment (MANSA) · patients with acute psychiatric disorders
1 finding from 1 review
Treatment satisfaction: average overall role score ‐ at discharge CAT ‐ Client Assessment of Treatment · patients with acute psychiatric disorders
1 finding from 1 review
Hospital admissions · patients with people with schizophrenia near or on discharge
DAY HOSPITAL showed no clear difference in service use: 1a. Admitted to hospital during study ‐ by 6 months compared with OUT‐PATIENT CARE (moderate certainty).
3 findings from 1 review
RR 0.58 [0.26, 1.33]
2 studies · 110 participants
Moderate
RR 0.73 [0.54, 1]
2 studies · 242 participants
Low
RR 0.71 [0.56, 0.89]
2 studies · 242 participants
Moderate
Global state: 1a. Number lost to · patients with people with schizophrenia near or on discharge
DAY HOSPITAL showed no clear difference in global state: 1a. Number lost to compared with OUT‐PATIENT CARE (moderate certainty).
2 findings from 1 review
Social functioning: 2a. Unemployed ‐ by 6 months · patients with people with schizophrenia near or on discharge
DAY HOSPITAL may leads to lower social functioning: 2a. Unemployed ‐ by 6 months compared with OUT‐PATIENT CARE (low certainty).
1 finding from 1 review
Social functioning: 2b. Unemployed ‐ beyond 12 months · patients with people with schizophrenia near or on discharge
DAY HOSPITAL showed no clear difference in social functioning: 2b. Unemployed ‐ beyond 12 months compared with OUT‐PATIENT CARE (moderate certainty).
1 finding from 1 review
Global state: no improvement ‐ short term · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Behaviour: deterioration of behaviour (categorised as reason to leave early) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review